ストックスクリーナーアプリを入手
4.73
0.63%
-0.03
前日終値:
$4.76
開ける：
$4.72
24時間の取引高:
36,330
Relative Volume:
0.23
時価総額：
$45.60M
収益：
-
当期純損益:
$-10.44M
株価収益率:
-3.5283
EPS:
-1.3406
ネットキャッシュフロー:
$-7.72M
1週間 パフォーマンス:
+2.38%
1か月 パフォーマンス:
-11.75%
6か月 パフォーマンス:
+10.77%
1年 パフォーマンス:
+86.96%
1日の値動き範囲:
$4.72
$4.969
1週間の範囲:
$4.45
$5.0532
52週間の値動き範囲:
$0.72
$20.32
Edesa Biotech Inc Stock (EDSA) Company Profile
Compare EDSA vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
4.73 | 45.89M | 0 | -10.44M | -7.72M | -1.3406 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Edesa Biotech Inc (EDSA) 最新ニュース
Edesa Biotech Enters Underwriting Deal With Guggenheim for $23.1M Equity Offering - TradingView
EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech? - Stocktwits
Edesa Biotech Prices $25 Million Stock-and-Warrant Offering to Fund Drug Pipeline - finance.biggo.com
Edesa Biotech Shares Tumble 13% on $25 Million Equity Offering - finance.biggo.com
Why Did EDSA Stock Rally More Than 70% Today? - Stocktwits
Edesa (EDSA) Quarter in Focus: EPS Does Not Reach the Reported Estimate for the Current Session; Share Move - vinanet.vn
Edesa Biotech Stock Sinks After Fresh Capital Raise - TradingView
Edesa Biotech raises USD 25m to fuel vitiligo Phase II - AllSci
Edesa Biotech prices $25M public offering at $5.50 per share By Investing.com - Investing.com Australia
Edesa Biotech prices $25M public offering at $5.50 per share - Investing.com Australia
Edesa Biotech Announces Pricing of $25.0 Million Public Offering - Yahoo Finance
Edesa Biotech stock tumbles on public offering launch By Investing.com - Investing.com Nigeria
Edesa Biotech Launches Public Offering of Common Shares, Warrants - marketscreener.com
Edesa Biotech Launches Public Offering to Fund Immuno-Inflammatory Pipeline - TipRanks
Edesa Biotech launches public offering of common shares - Investing.com
Edesa Biotech stock tumbles on public offering launch - Investing.com
Edesa Biotech Announces Proposed Public Offering of Common Shares and Warrants - Quiver Quantitative
Edesa Biotech Announces Proposed Public Offering - The Manila Times
Edesa Biotech(EDSA) Stock Options Chain | Quotes & News - Moomoo
Edesa Biotech Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
EDSA Q2 2026 Earnings: EPS Misses Consensus by 84.77% Despite Shares Rallying 5.61%Earnings Volatility Report - vinanet.vn
Brokers Set Expectations for Edesa Biotech FY2026 Earnings - MarketBeat
EDSA Q2 2026 Earnings: Wider-than-Expected Loss Amid Clinical-Stage SpendingShare Dilution Risk - vinanet.vn
EDSA Stock Soars More Than 700% So Far This Year: Wall Street Eyes Further Upside In Run Up To Acute Kidney Injury Data Reveal - Stocktwits
Edesa Biotech (NASDAQ:EDSA) Posts Earnings Results, Misses Expectations By $0.16 EPS - MarketBeat
Edesa Biotech Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K EDESA BIOTECH For: 13 August By Investing.com - Investing.com South Africa
Edesa Biotech Q3 loss widens 140% to $5.4M on rising R&D spend - scanx.trade
Edesa Biotech (EDSA) loss widens to $11.9M as R&D surges and cash tightens - Stock Titan
Edesa Reports $5.4 Million Q3 Loss as EB06 Phase 2 Site Activation Begins - Quiver Quantitative
Edesa Starts Activating First Vitiligo Trial Sites as Enrollment Nears - Stock Titan
Edesa Biotech Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Edesa Biotech (EDSA) Rallies 5.34% as Shares Test Key Resistance at $5.80Support Level Bounce - dars.gov.et
Edesa Biotech (EDSA) Edges Up 2.28% to $5.39 as Clinical-Stage Biotech Draws InterestStop Run - dars.gov.et
Edesa Biotech (EDSA) to Post Earnings on Monday - MarketBeat
Edesa Biotech Inc (EDSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
EDSA Q2 2026 Earnings: Wider Loss and 84.77% Negative Surprise Spotlight Pre-Revenue R&D OutlaysEarnings Stability Report - vinanet.vn
EDSA Q3'26 Earnings: EPS estimate is (0.43) USD - TradingView
Edesa Biotech (NASDAQ: EDSA) CEO receives 5,324 restricted share units - Stock Titan
EDSA Q3'26 Earnings: revenue estimate is 0 USD - TradingView
Edesa Biotech Inc (EDSA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Edesa Biotech Inc (EDSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Edesa Biotech Inc (EDSA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Edesa Biotech Inc (EDSA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Edesa Biotech Inc (EDSA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Edesa Biotech Inc (EDSA) Income Statement - TradingKey
Edesa Biotech (EDSA) Edges Lower Amid Thin Trading: Key Levels in FocusAI Trade Signals - Vinanet
Edesa Biotech Market Sentiment - Benzinga España
Edesa Biotech Inc (EDSA) Institutional Confidence - TradingKey
Edesa Biotech Inc (EDSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
EDSA|Edesa Biotech Inc|Price:5.250|Chg%:-0.410 - TradingKey
Edesa Biotech Inc (EDSA) 財務データ
収益
当期純利益
現金流量
EPS
Edesa Biotech Inc (EDSA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Nijhawan Pardeep | Chief Executive Officer |
Mar 10 '26 |
Buy |
6.60 |
1,000 |
6,599 |
628,813 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 05 '26 |
Buy |
3.90 |
10,000 |
39,000 |
402,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 04 '26 |
Buy |
4.26 |
10,000 |
42,560 |
392,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 03 '26 |
Buy |
3.63 |
10,000 |
36,300 |
382,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 02 '26 |
Buy |
2.00 |
2,000 |
4,000 |
627,813 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 02 '26 |
Buy |
2.28 |
1,000 |
2,280 |
372,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Feb 27 '26 |
Buy |
2.22 |
30,000 |
66,696 |
371,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Feb 26 '26 |
Buy |
1.58 |
20,571 |
32,480 |
615,797 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):